Who is sponsoring CheckMate 812?

CheckMate 812 is sponsored by Bristol-Myers Squibb.

What condition does CheckMate 812 study?

CheckMate 812 studies Hodgkin's Disease.

What drugs are being tested in CheckMate 812?

Interventions: Nivolumab, Brentuximab vedotin.

What is the status of CheckMate 812?

CheckMate 812 is currently TERMINATED.

Last reviewed 2024-01-10 · How we verify

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (CheckMate 812)

NCT03138499 PHASE3 TERMINATED Results posted

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE3
Status	TERMINATED
Enrolment	23
Start date	Mon Jun 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Feb 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hodgkin's Disease

Interventions

Nivolumab
Brentuximab vedotin

Countries

Japan, United States, Puerto Rico